Wuxi Shenrui Biological Products Co., Ltd., founded in 1999, covers a total area of approximately 10,000 m2 and is a high-tech biotech company integrating the R&D, production, and sales of medical devices and in vitro diagnostic reagents. The company has two subsidiaries: Wuxi Hesheng Medical Device Co., Ltd., located in the Life Science Industrial Park of Wuxi Huishan Economic Development Zone, with an operating area of over 1,000 m2, mainly engaged in the sales of clinical testing analytical instruments and in vitro diagnostic reagents; and Wuxi Zhengze Precision Medical Laboratory, with an investment and construction scale of over 3,000 m2, which is the first third-party medical laboratory in Wuxi jointly established by Shenrui Biology, Wuxi Huishan Economic Development Zone, and Wuxi (Huishan) Life Science Industrial Park, serving as an industry-university-research-medicine cooperation platform for clinical testing service outsourcing, scientific research cooperation and translation, technical research and tackling, and project application. Since 2011, the company has had 10 products recognized as provincial high-tech products and has applied for 35 invention patents (18 authorized). Its main products include: Human Papillomavirus (HPV) Nucleic Acid Detection Kit (PCR Fluorescence Method), Human EGFR Gene Mutation Detection Kit (Fluorescence PCR Method), Human K-ras Gene Mutation Detection Kit (Fluorescence PCR Method), Human B-raf Gene V600E Mutation Detection Kit (Fluorescence PCR Method), Trace Element Detection Kits (lead/iodine/calcium/zinc and other series), etc. The enterprise has been recognized as a high-tech enterprise and a provincial private technology enterprise. The company has established long-term industry-university-research strategic cooperative relationships with the Institute of Genomics of the Chinese Academy of Sciences, Fudan University, Nankai University, Gulou Hospital, and other institutions. Together with the Institute of Genomics of the Chinese Academy of Sciences and the Huishan District Government, it jointly established the Wuxi Institute of Health Sciences of the Institute of Genomics of the Chinese Academy of Sciences, focusing on the R&D and translation of new technologies and new targets in the field of precision medicine. In 2015, it successfully transferred the global PCT and domestic invention patents for non-invasive genetic testing of prostate cancer from the Institute of Genomics of the Chinese Academy of Sciences, becoming the first company in China to possess independent core technology for liquid biopsy. At present, this project is led by Sun Yinghao, academician of the Chinese Academy of Engineering, with Changhai Hospital of the Second Military Medical University as the lead, and jointly with the urology departments of 7 large tertiary hospitals, including Peking University First Hospital, the Third Affiliated Hospital of Sun Yat-sen University, Renji Hospital Affiliated to Shanghai Jiao Tong University, West China Hospital of Sichuan University, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, and the First Affiliated Hospital of Zhejiang University, conducting national multicenter clinical trials. This product achieves non-invasive detection of prostate cancer by detecting DNA methylation of exfoliated prostate cells in urine, featuring a completely new detection target, a completely new detection method, independent intellectual property rights, and filling a gap. It is the first liquid biopsy product in China to achieve early cancer diagnosis through epigenetic molecular markers, with great clinical value and market potential. This technology has obtained international PCT and domestic invention patent authorization (domestic patent: 201510027708.0; PCT/CN2015/099922), and has been funded by projects such as the National Key Basic Research Development Program (973), the Strategic Priority Research Program of the Chinese Academy of Sciences, and the National Natural Science Foundation of China. After years of accumulation, the company has now entered a stage of rapid development and welcomes talents from all sectors to join. The company will provide you with a good career development platform, a comfortable working environment, and, upon employment, industry-competitive salary and benefits.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows